C10orf71

Summary

C10orf71 (chromosome 10 open reading frame 71, HGNC:26973) is a protein-coding gene on chromosome 10q11.23, encoding Cardiac-enriched FHL2-interacting protein (Q711Q0). Is an activator of the calcineurin/NFAT signaling pathway in cardiomyocytes, and is involved in myocardium morphogenesis, and regulation of myocardium mass and cardiac contractile function.

Predicted to be involved in positive regulation of calcineurin-NFAT signaling cascade. Predicted to act upstream of or within cardiac muscle cell contraction; cardiac muscle cell differentiation; and heart morphogenesis. Predicted to be located in cytoplasm. Predicted to be active in Z disc.

Source: NCBI Gene 118461 — RefSeq curated summary.

At a glance

• Gene–disease (curated): dilated cardiomyopathy (Limited, GenCC)
• GWAS associations: 4
• Clinical variants (ClinVar): 34 total — 4 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 8
• MANE Select transcript: NM_001135196

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26973
Approved symbol	C10orf71
Name	chromosome 10 open reading frame 71
Location	10q11.23
Locus type	gene with protein product
Status	Approved
Aliases	FLJ45913, CEFIP
Ensembl gene	ENSG00000177354
Ensembl biotype	protein_coding
OMIM	621202
Entrez	118461

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000374144, ENST00000470615, ENST00000862410, ENST00000862411, ENST00000950697

RefSeq mRNA: 1 — MANE Select: NM_001135196 NM_001135196

CCDS: CCDS44387

Canonical transcript exons

ENST00000374144 — 3 exons

Exon	Start	End
ENSE00001462586	49322402	49327492
ENSE00001646488	49316145	49316247
ENSE00001901319	49299170	49299233

Expression profiles

Bgee: expression breadth ubiquitous, 112 present calls, max score 98.25.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.4107 / max 329.7076, expressed in 113 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
104881	0.4070	63
104880	0.2906	63
104882	0.2195	38
104883	0.2081	29
104885	0.1481	34
104884	0.0938	26
104879	0.0436	24

Top tissues by expression

236 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.25	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.85	gold quality
skeletal muscle tissue	UBERON:0001134	97.47	gold quality
left ventricle myocardium	UBERON:0006566	97.38	gold quality
tibialis anterior	UBERON:0001385	96.91	gold quality
quadriceps femoris	UBERON:0001377	96.89	gold quality
vastus lateralis	UBERON:0001379	96.80	gold quality
biceps brachii	UBERON:0001507	96.47	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	96.21	gold quality
cardiac muscle of right atrium	UBERON:0003379	95.44	gold quality
gastrocnemius	UBERON:0001388	95.10	gold quality
deltoid	UBERON:0001476	94.55	gold quality
apex of heart	UBERON:0002098	94.14	gold quality
muscle of leg	UBERON:0001383	93.82	gold quality
body of tongue	UBERON:0011876	92.43	gold quality
muscle tissue	UBERON:0002385	91.34	gold quality
myocardium	UBERON:0002349	90.26	gold quality
heart left ventricle	UBERON:0002084	88.60	gold quality
cardiac ventricle	UBERON:0002082	88.41	gold quality
tongue	UBERON:0001723	82.91	gold quality
cardiac atrium	UBERON:0002081	82.62	gold quality
right atrium auricular region	UBERON:0006631	81.96	gold quality
heart	UBERON:0000948	81.24	gold quality
heart right ventricle	UBERON:0002080	79.32	gold quality
superior surface of tongue	UBERON:0007371	75.79	gold quality
pharyngeal mucosa	UBERON:0000355	74.36	gold quality
kidney epithelium	UBERON:0004819	71.88	gold quality
epithelial cell of pancreas	CL:0000083	69.08	gold quality
tendon of biceps brachii	UBERON:0008188	66.91	gold quality
vena cava	UBERON:0004087	66.71	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.45

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 3)

• Data suggest that CEFIP (cardiac-enriched FHL2-interacting protein) interacts with FHL2 (four and a half LIM domains protein-2) and modulates calcineurin signaling in cardiomyocytes; CEFIP is located at sarcomeric z-disc and is up-regulated in several models of cardiomegaly. (PMID:28717008)
• Autosomal recessive congenital cataract is associated with a novel 4-bp splicing deletion mutation in a novel C10orf71 human gene. (PMID:37179318)
• Frameshift variants in C10orf71 cause dilated cardiomyopathy in human, mouse, and organoid models. (PMID:38950288)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	3425401B19Rik	ENSMUSG00000071540
rattus_norvegicus	C16h10orf71	ENSRNOG00000049942

Protein

Protein identifiers

Cardiac-enriched FHL2-interacting protein — Q711Q0 (reviewed: Q711Q0)

All UniProt accessions (1): Q711Q0

UniProt curated annotations — full annotation on UniProt →

Function. Is an activator of the calcineurin/NFAT signaling pathway in cardiomyocytes, and is involved in myocardium morphogenesis, and regulation of myocardium mass and cardiac contractile function.

Subunit / interactions. Interacts with FHL2.

Subcellular location. Cytoplasm. Myofibril. Sarcomere. Z line.

Tissue specificity. Expressed in the heart and skeletal muscle.

Disease relevance. Cardiomyopathy, dilated, 1QQ (CMD1QQ) [MIM:621251] A form of dilated cardiomyopathy, a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. CMD1QQ is an autosomal dominant form. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (2)

UniProt ID	Names	Canonical?
Q711Q0-1	1	yes
Q711Q0-3	3

RefSeq proteins (1): NP_001128668* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR027838	DUF4585	Domain
IPR052303	CEFIP	Family

Pfam: PF15232

UniProt features (54 total): compositionally biased region 18, sequence variant 12, region of interest 10, sequence conflict 7, modified residue 4, splice variant 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q711Q0-F1	42.08	0.02

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 120, 323, 470, 816

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 48 (showing top): GOBP_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, MEF2_02, GOBP_POSITIVE_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, HAND1E47_01, OCT1_B, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, MEF2_Q6_01, CTAWWWATA_RSRFC4_Q2, GOCC_I_BAND, WGGAATGY_TEF1_Q6, VDR_Q6, OCT_Q6, GRYDER_PAX3FOXO1_ENHANCERS_KO_DOWN, GOBP_CALCINEURIN_MEDIATED_SIGNALING

GO Biological Process (5): heart morphogenesis (GO:0003007), cardiac muscle cell differentiation (GO:0055007), positive regulation of calcineurin-NFAT signaling cascade (GO:0070886), cardiac muscle cell contraction (GO:0086003), heart development (GO:0007507)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): Z disc (GO:0030018), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
heart development	1
animal organ morphogenesis	1
cardiocyte differentiation	1
cardiac muscle tissue development	1
striated muscle cell differentiation	1
calcineurin-NFAT signaling cascade	1
regulation of calcineurin-NFAT signaling cascade	1
positive regulation of calcineurin-mediated signaling	1
cardiac muscle contraction	1
actin-mediated cell contraction	1
animal organ development	1
circulatory system development	1
binding	1
I band	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

2596 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
C10orf71	FHL2	Q14192	526
C10orf71	SIPA1L3	O60292	525
C10orf71	OBSL1	O75147	523
C10orf71	ANO8	Q9HCE9	521
C10orf71	ENOX1	Q8TC92	518
C10orf71	ARHGAP28	Q9P2N2	512
C10orf71	SPAG11A	Q6PDA7	507
C10orf71	TM9SF4	Q92544	496
C10orf71	MYO18B	Q8IUG5	473
C10orf71	LIPN	Q5VXI9	458
C10orf71	A0A0G2JN59	A0A0G2JN59	419
C10orf71	DYNLT4	Q5JR98	417
C10orf71	DALRD3	Q5D0E6	399
C10orf71	RNF133	Q8WVZ7	398
C10orf71	SPIN4	Q56A73	377

IntAct

4 interactions, top by confidence:

A	B	Type	Score
CEFIP	PCNA	psi-mi:“MI:0915”(physical association)	0.370
CEFIP	FNTA	psi-mi:“MI:0914”(association)	0.350
CEFIP	FGF1	psi-mi:“MI:0914”(association)	0.350

BioGRID (16): DYRK1B (Affinity Capture-MS), DYRK1A (Affinity Capture-MS), DCAF7 (Affinity Capture-MS), FNTB (Affinity Capture-MS), FNTA (Affinity Capture-MS), C10orf71 (Affinity Capture-MS), FNTB (Affinity Capture-MS), DCAF7 (Affinity Capture-MS), DYRK1A (Affinity Capture-MS), DYRK1B (Affinity Capture-MS), FNTA (Affinity Capture-MS), FGF1 (Affinity Capture-MS), MAP7D3 (Cross-Linking-MS (XL-MS)), C10orf71 (Cross-Linking-MS (XL-MS)), C10orf71 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A096MK47, A0JNH1, A6H5Y1, A6NCI8, A6NFA0, A6NGG8, B2RQL2, D3Z1D3, D3ZMK9, E9Q286, E9Q309, M0RD54, O14513, P51816, Q01613, Q03172, Q05860, Q2M2Z5, Q32LN6, Q3MHH3, Q3UXL4, Q3V0A6, Q569L8, Q571I4, Q5DTX6, Q5FW52, Q5HYW2, Q5R9I1, Q5VT06, Q5VWP3, Q60988, Q66HG9, Q68DA7, Q6P1W5, Q6P9P0, Q6PAC4, Q6PG16, Q711Q0, Q7TP36, Q7TSA6

Diamond homologs: D3Z1D3, M0RD54, Q711Q0, D6RIA3, E0CYV9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

34 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	1
Uncertain significance	18
Likely benign	1
Benign	7

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
3906944	C10ORF71, 16-BP DEL, NT1057	Pathogenic
3906945	NM_001135196.2(C10orf71):c.1095del (p.Ser367fs)	Pathogenic
3906946	NM_001135196.2(C10orf71):c.1914del (p.Glu638fs)	Pathogenic
3906947	NM_001135196.2(C10orf71):c.353dup (p.Pro119fs)	Pathogenic
4531453	NM_001135196.2(C10orf71):c.1399C>T (p.Arg467Ter)	Likely pathogenic

SpliceAI

672 predictions. Top by Δscore:

Variant	Effect	Δscore
10:49316244:ACAG:A	donor_gain	0.9900
10:49316143:A:AG	acceptor_gain	0.9800
10:49316143:AGATG:A	acceptor_gain	0.9800
10:49316144:G:GG	acceptor_gain	0.9800
10:49316144:GATGG:G	acceptor_gain	0.9800
10:49316243:AACAG:A	donor_loss	0.9800
10:49316245:CAG:C	donor_loss	0.9800
10:49316246:AG:A	donor_loss	0.9800
10:49316247:GGTAT:G	donor_loss	0.9800
10:49316248:G:C	donor_loss	0.9800
10:49316249:T:A	donor_loss	0.9800
10:49316139:TTCCA:T	acceptor_loss	0.9700
10:49316141:CCA:C	acceptor_loss	0.9700
10:49316143:A:G	acceptor_loss	0.9700
10:49316144:G:GC	acceptor_loss	0.9700
10:49322401:GA:G	acceptor_gain	0.9700
10:49316143:AGAT:A	acceptor_gain	0.9600
10:49316144:GATG:G	acceptor_gain	0.9600
10:49322400:A:AG	acceptor_gain	0.9600
10:49322401:G:GG	acceptor_gain	0.9600
10:49316144:GAT:G	acceptor_gain	0.9500
10:49322399:CAG:C	acceptor_gain	0.9500
10:49322400:AGA:A	acceptor_gain	0.9500
10:49322401:GAG:G	acceptor_gain	0.9500
10:49322401:GAGAA:G	acceptor_gain	0.9500
10:49322401:GAGA:G	acceptor_gain	0.9300
10:49299229:TTTAG:T	donor_loss	0.9100
10:49299230:TTAG:T	donor_loss	0.9100
10:49299231:TAGGT:T	donor_loss	0.9100
10:49299232:AGGTA:A	donor_loss	0.9100

AlphaMissense

9420 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:49322640:T:C	L32P	0.996
10:49322649:G:C	R35P	0.996
10:49322655:T:C	F37S	0.996
10:49326063:T:A	V1173D	0.996
10:49326090:G:C	R1182P	0.996
10:49322654:T:C	F37L	0.995
10:49322656:C:A	F37L	0.995
10:49322656:C:G	F37L	0.995
10:49326093:G:C	R1183P	0.995
10:49322651:G:C	A36P	0.994
10:49322982:T:C	L146P	0.993
10:49323350:T:C	F269L	0.993
10:49323352:T:A	F269L	0.993
10:49323352:T:G	F269L	0.993
10:49324065:G:C	R507P	0.993
10:49326087:T:C	L1181P	0.993
10:49326375:T:C	L1277P	0.993
10:49322660:A:C	S39R	0.992
10:49322662:T:A	S39R	0.992
10:49322662:T:G	S39R	0.992
10:49322993:T:C	F150L	0.992
10:49322995:C:A	F150L	0.992
10:49322995:C:G	F150L	0.992
10:49324074:T:A	V510D	0.992
10:49326075:C:T	T1177I	0.992
10:49326095:G:C	A1184P	0.992
10:49323359:A:C	S272R	0.991
10:49323361:T:A	S272R	0.991
10:49323361:T:G	S272R	0.991
10:49324053:T:C	L503P	0.991

dbSNP variants (sampled 300 via entrez): RS1000097504 (10:49302945 T>C), RS1000106652 (10:49320607 A>C,T), RS1000168168 (10:49301622 C>T), RS1000171062 (10:49325027 G>A,C,T), RS1000182534 (10:49313901 G>A), RS1000365254 (10:49308168 G>C,T), RS1000379148 (10:49325820 A>C), RS1000552214 (10:49296322 G>A,C), RS1000623241 (10:49314204 A>C), RS1000916106 (10:49326237 A>G,T), RS1000993499 (10:49318771 A>C,G), RS1001219669 (10:49312739 C>A), RS1001391775 (10:49306999 C>G), RS1001441046 (10:49297692 T>A), RS1001522557 (10:49319464 C>T)

Disease associations

OMIM: gene MIM:621202 | disease phenotypes: MIM:621251

GenCC curated gene-disease

Disease	Classification	Inheritance
dilated cardiomyopathy	Limited	Autosomal dominant

Mondo (2): dilated cardiomyopathy (MONDO:0005021), cardiomyopathy, dilated, 1QQ (MONDO:0979239)

Orphanet (1): Dilated cardiomyopathy (Orphanet:217604)

HPO phenotypes

8 total (8 of 8 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0001644	Dilated cardiomyopathy
HP:0003621	Juvenile onset
HP:0011462	Young adult onset
HP:0011664	Left ventricular noncompaction cardiomyopathy
HP:0012663	Mildly reduced left ventricular ejection fraction
HP:0012666	Severely reduced left ventricular ejection fraction
HP:0034307	Elevated left ventricular end-diastolic diameter

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001834_4	Oleic acid (18:1n-9) levels	5.000000e-06
GCST002446_3	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)	5.000000e-06
GCST010320_15	PR interval	9.000000e-10
GCST010321_21	PR interval	3.000000e-11

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005680	omega-6 polyunsaturated fatty acid measurement
EFO:0004462	PR interval

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

8 total (human), top 8 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, increases methylation	1
Sunitinib	decreases expression	1
Fulvestrant	increases methylation, affects cotreatment	1
Benzo(a)pyrene	increases methylation, affects methylation	1
Doxorubicin	decreases expression	1
Triclosan	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1

Clinical trials (associated diseases)

158 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00374465	PHASE4	UNKNOWN	Therapy With Verapamil or Carvedilol in Chronic Heart Failure
NCT01293903	PHASE4	COMPLETED	Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy
NCT01557140	PHASE4	COMPLETED	A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
NCT01917149	PHASE4	COMPLETED	Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
NCT02115581	PHASE4	COMPLETED	Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
NCT06236022	PHASE4	RECRUITING	The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
NCT00333827	PHASE3	COMPLETED	Cell Therapy In Dilated Cardiomyopathy
NCT00505154	PHASE3	COMPLETED	Effect of Rosuvastatin on Left Ventricular Remodeling
NCT01223703	PHASE3	COMPLETED	PUFAs and Left Ventricular Function in Heart Failure
NCT01583114	PHASE3	TERMINATED	PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors
NCT01914081	PHASE3	UNKNOWN	Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
NCT02989181	PHASE3	UNKNOWN	Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea
NCT03439514	PHASE3	TERMINATED	A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT05849766	PHASE3	COMPLETED	Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
NCT06250257	PHASE3	RECRUITING	Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
NCT00629018	PHASE2	COMPLETED	Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
NCT00629096	PHASE2	COMPLETED	Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy
NCT00765518	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
NCT00847964	PHASE2	COMPLETED	Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery
NCT01020968	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
NCT01302171	PHASE2	COMPLETED	Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy
NCT01350310	PHASE2	COMPLETED	Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy
NCT02133911	PHASE2	COMPLETED	A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
NCT03071653	PHASE2	SUSPENDED	Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study
NCT03572660	PHASE2	ACTIVE_NOT_RECRUITING	Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM
NCT03775070	PHASE2	COMPLETED	Simvastatin Therapy in Patients With Dilated Cardiomyopathy.
NCT04405804	PHASE2	UNKNOWN	Early Administration of Ivabradine in Children With Heart Failure
NCT05410873	PHASE2	COMPLETED	Examining the Effects of Mitochondrial Oxidative Stress in DCM
NCT06632834	PHASE2	RECRUITING	Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation
NCT00585546	PHASE1	TERMINATED	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
NCT02293603	PHASE1	UNKNOWN	Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)
NCT03062956	PHASE1	COMPLETED	A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491
NCT03129568	PHASE1	COMPLETED	Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy
NCT04982081	PHASE1	UNKNOWN	Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
NCT06381466	PHASE1	TERMINATED	A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
NCT06464588	PHASE1	RECRUITING	A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
NCT06902896	PHASE1	COMPLETED	Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
NCT07137338	PHASE1	RECRUITING	A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
NCT07241104	PHASE1	RECRUITING	A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy